Pfizer Inc.
Pfizer Research Technology Center (RTC)
620 Memorial Drive
Cambridge
Massachusetts
02139
United States
Tel: 617-551-3000
Fax: 617-551-3111
Website: http://www.pfizer.com/
About Pfizer Inc.
The Pfizer Research Technology Center (RTC) in Cambridge, MA houses cutting edge research groups focused on RNAi therapeutics, Systems Biology and Biological Profiling, Regenerative Medicine and Computational Sciences.
Headquartered at the RTC, and comprising research groups in Cambridge and Düsseldorf, the goal of Pfizer RNAi Therapeutics is clear - delivering RNAi therapies to meet our patient needs and in doing so helping Pfizer become a top tier biotherapeutics company.
Pfizer Regenerative Medicine is collaborating with local experts to develop Stem Cell Therapies to treat diseases.
The Systems Biology, Biological Profiling and Computational Sciences groups are using their niche skills and expertise to focus on increasing the effectiveness of the research process through better target selection, reduced attrition and the ability to manipulate and manage data to support the research process.
Without the constraints of a therapeutic area portfolio, RTC colleagues are free to apply cutting-edge techniques and technologies with broad utility across different therapeutic areas.
The RTC is located in one of the richest scientific environments in the world, surrounded by more than 300 biotechnology companies and thousands of scientific innovators in world-leading research hospitals and academic institutions. A key element in the success of the RTC is the growing and dynamic portfolio of partnerships with these innovators, focused on addressing the strategic needs of the site and of Pfizer's research division.
The RTC aims to balance the strength of Pfizer R&D with the nimble feel of a small biotech, and creates an exciting and team-based scientific environment for 150 colleagues, with a wide range of scientific skills and experience. The working environment emphasizes collaboration and cooperation with most scientific questions solved through the work of a cross-disciplinary team. The unique working environment - truly a small biotech with the backing of the largest research budget in the industry - supports the unique science of the site.
For more information, please visit www.pfizercambridge.com
113 articles about Pfizer Inc.
-
Pfizer Declares Fourth-Quarter 2021 Dividend
9/23/2021
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a 39-cent fourth-quarter 2021 dividend on the company’s common stock, payable December 6, 2021, to holders of the Common Stock of record at the close of business on November 5, 2021.
-
Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Upcoming Healthcare Conferences
9/7/2021
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to two webcasts of discussions with Pfizer executives at two upcoming healthcare conferences.
-
Pfizer Announces New Chief Business Innovation Officer
8/26/2021
Pfizer Inc. (NYSE: PFE) today announced that Aamir Malik has joined the company as Executive Vice President and Chief Business Innovation Officer.
-
Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older
8/23/2021
Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for COMIRNATY® (COVID-19 Vaccine, mRNA) to prevent COVID-19 in individuals 16 years of age and older.
-
Pfizer and BioNTech to Provide U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.
7/23/2021
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. government has purchased an additional 200 million doses of the Pfizer-BioNTech COVID-19 Vaccine.
-
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471
7/22/2021
Arvinas, Inc. and Pfizer Inc. today announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader.
-
Pfizer and BioNTech Announce Collaboration With Biovac to Manufacture and Distribute COVID-19 Vaccine Doses Within Africa
7/21/2021
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a letter of intent with The Biovac Institute (Pty) Ltd, known as “Biovac,” a Cape Town-based, South African biopharmaceutical company, to manufacture the Pfizer-BioNTech COVID-19 Vaccine for distribution within the African Union.
-
U.S. FDA Approves PREVNAR 20™, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older
6/9/2021
U.S. FDA Approves PREVNAR 20 ™ , Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older.
-
Pfizer Acquires Amplyx Pharmaceuticals
4/28/2021
Deal expands anti-infectives pipeline with addition of novel antifungal Phase 2 candidate, Fosmanogepix (APX001) Opportunity to advance Pfizer’s expertise and deep heritage in infectious disease
-
Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study
4/1/2021
Analysis of 927 confirmed symptomatic cases of COVID-19 demonstrates BNT162b2 is highly effective with 91.3% vaccine efficacy observed against COVID-19, measured seven days through up to six months after the second dose
-
Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared
3/11/2021
Dramatically lower COVID-19 disease incidence rates observed in individuals fully vaccinated with the Pfizer-BioNTech vaccine, based on real-world data gathered by the Israel Ministry of Health Data suggest Pfizer-BioNTech vaccine prevents asymptomatic SARS-CoV-2 infection Latest data analysis finds unvaccinated individuals were 44 times more likely to develop symptomatic COVID-19 and 29 times more likely to die from COVID-19
-
Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) in Multiple Myeloma
2/17/2021
Pfizer Inc. (NYSE:PFE) today announced that the first participant has been dosed in the registration-enabling Phase 2 MagnetisMM-3 study (NCT04649359) of elranatamab (PF-06863135), an investigational B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody, in patients with relapsed/refractory multiple myeloma.
-
U.S. FDA Approves PANZYGA® for the Treatment of Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
2/12/2021
U.S. FDA Approves PANZYGA ® for the Treatment of Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) The first and only FDA-approved intravenous immunoglobulin with two maintenance dosing options for CIDP
-
4D pharma Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate MRx0518 in Combination with BAVENCIO® for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
2/8/2021
4D pharma Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate MRx0518 in Combination with BAVENCIO ® for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
-
Pfizer Confirms U.S. Patent Term Extension for IBRANCE® (palbociclib) Until March 2027
2/5/2021
Pfizer Confirms U.S. Patent Term Extension for IBRANCE ® (palbociclib) Until March 2027
-
Imcyse Enters into Research Collaboration and License Agreement for its Imotope(TM) Technology with Pfizer in Rheumatoid Arthritis
2/3/2021
Imcyse and Pfizer to collaborate to develop Imotope TM candidates to potentially treat Rheumatoid Arthritis Pfizer to lead clinical development and commercialization activities
-
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2020 RESULTS AND RELEASES 5-YEAR PIPELINE METRICS
2/2/2021
Upjohn Business (1) Now Accounted for as a Discontinued Operation for All Periods Presented, Excluded from Adjusted (2) Results Full-Year 2020 Revenues of $41.9 Billion, Which Now Exclude Upjohn (1) , Reflect 3% Operational Growth; When the Impact from Consumer Healthcare (1) and the $154 Million of Sales of BNT162b2 are Excluded, Full-Year 2020 Revenues Grew 8% Operationally
-
Pfizer Shares Co-Primary Endpoint Results from Post-Marketing Required Safety Study of XELJANZ® (tofacitinib) in Subjects with Rheumatoid Arthritis (RA)
1/27/2021
Pfizer Inc. (NYSE: PFE) announced today co-primary endpoint results from a recently completed post-marketing required safety study, ORAL Surveillance (A3921133; NCT02092467).
-
Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
1/26/2021
Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the Phase 3 SPIRIT long-term extension study of the investigational once-daily relugolix combination therapy
-
Pfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative
1/12/2021
First four investments of new program created to support clinical-stage biotechnology companies New investments include companies focused on Oncology, Rare Disease, and Inflammation & Immunology